“The monoclonal antibody vedolizumab may reduce biliary inflammation in patients with primary sclerosing cholangitis and comorbid inflammatory bowel disease, according to early, open-label study findings reported at the meeting sponsored by the European Association for the Study of the Liver” –according to GIHepNews: Biliary inflammation reduced by IBD drug
“Vedolizumab given to 27 patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) resulted in a 50% reduction or normalization of serum alkaline phosphatase levels in 17 cases (63%).”
This was an open-label, proof-of-concept study involving 27 patients aged 25-30 years with PSC and comorbid IBD.
My take: This is interesting but needs a lot more study.
Pingback: Primary Sclerosing Cholangitis 2016 | gutsandgrowth
Pingback: Should We Care About Subclinical Primary Sclerosing Cholangitis with Inflammatory Bowel Disease? | gutsandgrowth
Pingback: Liver Problems with Inflammatory Bowel Disease | gutsandgrowth
Pingback: Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis | gutsandgrowth